

Title: RDF1127-22 - Asthma Treatments

---

Reference Number: RDF1127-22

Date of Response: 06/01/22

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

*I hope that you are well. I have a freedom of information request that I need your help with. I understand the pressures the entire NHS is currently under, but I would greatly appreciate your assistance. Could you please answer the questions below:*

1. *How many patients have been treated (for any condition) in the last 4 months with:*

- *Benralizumab: 22.*
- *Dupilumab: ≤5.*
- *Omalizumab: ≤5.*
- *Reslizumab: Nil.*
- *Mepolizumab: Nil.*
- *Tezepelumab: Nil.*

Answer: Please see above. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles.

In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed. These figures are withheld under Section 40(2) due to low patient numbers. The disclosure of which could risk the identification of those patients and breach Caldicott principles.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

2. *Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:*

- *Age 6-11: Nil.*
- *Age 12-17: Nil.*
- *Age 18 and above: 26.*

Answer: Please see above.

3. *How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:*

- *Dupilumab: ≤5.*
- *Omalizumab: ≤5.*

Answer: Please see above.